RxDoctor Payments Data

Uma Srivatsa, MD

Cardiovascular Disease · Sacramento, CANPI 1598747800

Payments from drug & device makers

$63,688in general payments, 2019–2025

Across 304 payments — averaging $209.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biotronik Inc.$49K
  • Abbott$9K
  • Medtronic$3K
  • Altathera Pharmaceuticals LLC$1K
  • Boston Scientific$449
  • Biosense Webster, Inc.$370
  • plus $233 from 4 others

What the payments were for

  • Consulting fees$7,15049%
  • Speaking & faculty fees$1,0007%
  • Travel & lodging$4,15929%
  • Food & beverage$2,05714%
  • Education$1301%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$63,688 in reported general payments places this provider in the 85th percentile of 2,184 cardiovascular disease providers in California.

See all cardiovascular disease providers in California

Medicare billing

Part B allowed, 2024
$163,247
Medicare patients
573
Services billed
2,118

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban145$169,536
JardianceEmpagliflozin33$35,542
XareltoRivaroxaban16$25,368
EntrestoSacubitril/Valsartan26$18,812
Amiodarone Hcl103$3,552
Metoprolol Succinate107$1,969
Flecainide Acetate38$1,280
Verapamil ErVerapamil Hcl12$418
Metoprolol Tartrate38$348
Losartan Potassium22$296
Atorvastatin Calcium34$174
Amlodipine Besylate20$152
Carvedilol15$128
Furosemide22$55
Lisinopril12$22

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$25$18,81226 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,184 cardiovascular disease providers in California.

Other cardiovascular disease in Sacramento

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →